Lilly Xigris Add-On Medicare Payment Decision Awaits Further CMS Analysis
Executive Summary
The Centers for Medicare & Medicaid Services may consider providing add-on Medicare payments for Lilly's sepsis agent Xigris for a narrower patient population than FDA's approved indication
You may also be interested in...
Xigris Medicare “Add-On” Payments Approved; CMS Estimates 50,000 Cases
The Centers for Medicare & Medicaid Services is estimating that the Medicare market for Lilly's Xigris will be $340 mil. in fiscal year 2003
Zyvox Not Major Treatment Expense, CMS Says; Add-On Payments Denied
Pharmacia's Zyvox is not a significant factor in the total cost of treating patients receiving the product, the Centers for Medicare & Medicaid Services determined in denying add-on payments for the antibiotic
Zyvox Not Major Treatment Expense, CMS Says; Add-On Payments Denied
Pharmacia's Zyvox is not a significant factor in the total cost of treating patients receiving the product, the Centers for Medicare & Medicaid Services determined in denying add-on payments for the antibiotic